Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2000

View Archived Issues

NIAID awards grants for drug and vaccine development

Epicyte receives grants for sexual health applications

Advanced Biotherapy's anti-interferon gamma drug shows promise in the clinic

Clinical trial results for IL-2/SEB combination therapy for melanoma positive

PI-88's novel mechanism of action revealed; compound enters two new trials

NIDA grant awarded to Nabi for nicotine vaccine research

Myriad reports location of prostate cancer susceptibility gene

AxyS selects lead compound in asthma program

Ertapenem displays activity against a wide range of anaerobes causing intraabdominal infection

Salus receives SBIR grant for cystic fibrosis research

FDA approves first and only once-monthly contraceptive for women

Periostat now available in the U.K., its first European market

Coulter's Bexxar assigned priority review status by FDA

Parke-Davis reports SAR investigations on novel non-nucleoside antiviral agents

Initial evaluation of female sexual response using MS-325

Positive effects of PARP inhibitor in animal model of acute inflammation

Preclinical data support clinical trials of repifermin in ulcerative colitis

Marine natural product shows promise for hyperproliferative and inflammatory conditions

CRL-8256, with potential in cancer chemotherapy, emerges from joint French and Belgian research

Favorable ML-3000 clinical data presented during OARSI congress

Numerous lead compounds emerge from Versicor's oxazolidinone combinatorial libraries

Sulfonamides designed by two major labs as potential Alzheimer's disease therapies

NOS inhibitors in the Pfizer pipeline reported in patent literature

Novel target for anticancer therapy and new compounds discovered at Klinge

Roche's new NK1 receptor antagonists intended particularly for depression and emesis

New PDE4 inhibitors and methods of treating asthma

Boehringer Ingelheim identifies new series of cytokine-inhibitory antiinflammatory agents

International patent coverage obtained for new thrombin inhibitors from Boehringer Ingelheim

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.